1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

 
• By Alaric DeArment

After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.

AnaptysBio may have a better shot at a rarer skin condition with imsidolimab after acne trial failure • Source: Shutterstock

The market opportunity appears further narrowed for AnaptysBio, Inc.’s monoclonal antibody against the interleukin-36 receptor, imsidolimab, after it failed as a treatment for acne. Nevertheless, the drug still has a shot at tackling two orphan dermatological conditions that could enable it to command a higher price on the market.

AnaptysBio said after markets closed on 14 March that the Phase II ACORN clinical trial in moderate-to-severe acne did not meet its primary and secondary endpoints, and the data in fact showed that the drug underperformed placebo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.